Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: A baby will be included if she/he:~* is a singleton~* is breastfed at day 7 by her/his mother and her/his mother intends to continue breastfeeding for at least 6 months~* has a post-partum blood sample with a negative HIV-1 DNA PCR test result at day 7 (+/- 2 days)~* has received ART as part of PMTCT~and if the mother:~* has reached the local legal age for participating in medical research studies~* is shown to be HIV-1 infected (with or without HIV-2 infection) and is not eligible for HAART or is not taking HAART~* has received a perinatal antiretroviral prophylaxis during pregnancy and delivery,~* has a CD4 count above the threshold of HAART initiation in pregnant women according to the national recommendation in each site (minimum 230 cells/µL),~* resides within the study area and is not intending to move out of the area in the next year~* gives assent for the infant to participate and gives consent to participate~Exclusion Criteria:~* S/he presents clinical symptoms and/or biological abnormalities equal to or greater than grade II of the ANRS classification for adverse event on the day of enrolment~* S/he presents with serious congenital malformation(s)~* Her/his birth weight is lower than 2.0 kg~* Her/his antiretroviral prophylaxis is extending beyond day 7~* The mother has participated in the trial for a previous pregnancy~* S/he and her/his mother are participating in another clinical trial on the day of enrolment

- Gender: ALL
- Minimum Age: 5 Days
- Maximum Age: 9 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): infant peri-exposure prophylaxis with lopinavir/ritonavir
- 2 (Type: ACTIVE_COMPARATOR): infant peri-exposure prophylaxis with lamivudine

Based on this trial design, predict the completion outcome and termination type (if applicable).